Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P E Greenberg

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Pharmacoeconomics|October 28, 1999
Using healthcare claims data for outcomes research and pharmacoeconomic analysesH G Birnbaum, P Y Cremieux, P E Greenberg, et al.
Pharmacoeconomics|February 8, 2000
Pharmacoeconomics and health policy. Current applications and prospects for the futureP E Greenberg, A Arcelus, H G Birnbaum, et al.
Journal of Occupational and Environmental Medicine|June 30, 2000
Direct and indirect costs of rheumatoid arthritis to an employerH G Birnbaum, M Barton, P E Greenberg, et al.
Psychopharmacology Bulletin|January 1, 1996
Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study GroupS N Finkelstein, E R Berndt, P E Greenberg, et al.
Health Affairs (Project Hope)|September 25, 1999
Depression in the workplace: effects on short-term disabilityR C Kessler, C Barber, H G Birnbaum, et al.
Journal of Health Economics|September 4, 1998
Workplace performance effects from chronic depression and its treatmentE R Berndt, S N Finkelstein, P E Greenberg, et al.
Journal of Occupational and Environmental Medicine|February 24, 2001
Depression and work productivity: the comparative costs of treatment versus nontreatmentG E Simon, C Barber, H G Birnbaum, et al.
The Journal of Clinical Psychiatry|August 24, 1999
The economic burden of anxiety disorders in the 1990sP E Greenberg, T Sisitsky, R C Kessler, et al.
Neurology|June 17, 2009
The risks and costs of multiple-generic substitution of topiramateM S Duh, P E Paradis, D Latrémouille-Viau, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Pharmacoeconomics|October 28, 1999
Using healthcare claims data for outcomes research and pharmacoeconomic analysesH G Birnbaum, P Y Cremieux, P E Greenberg, et al.
Pharmacoeconomics|February 8, 2000
Pharmacoeconomics and health policy. Current applications and prospects for the futureP E Greenberg, A Arcelus, H G Birnbaum, et al.
Journal of Occupational and Environmental Medicine|June 30, 2000
Direct and indirect costs of rheumatoid arthritis to an employerH G Birnbaum, M Barton, P E Greenberg, et al.
Psychopharmacology Bulletin|January 1, 1996
Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study GroupS N Finkelstein, E R Berndt, P E Greenberg, et al.
Health Affairs (Project Hope)|September 25, 1999
Depression in the workplace: effects on short-term disabilityR C Kessler, C Barber, H G Birnbaum, et al.
Journal of Health Economics|September 4, 1998
Workplace performance effects from chronic depression and its treatmentE R Berndt, S N Finkelstein, P E Greenberg, et al.
Journal of Occupational and Environmental Medicine|February 24, 2001
Depression and work productivity: the comparative costs of treatment versus nontreatmentG E Simon, C Barber, H G Birnbaum, et al.
The Journal of Clinical Psychiatry|August 24, 1999
The economic burden of anxiety disorders in the 1990sP E Greenberg, T Sisitsky, R C Kessler, et al.
Neurology|June 17, 2009
The risks and costs of multiple-generic substitution of topiramateM S Duh, P E Paradis, D Latrémouille-Viau, et al.
Pageof 2